REVENIO

Revenio Group Corporation to transfer shares related to the share-based incentive scheme for 2019-2021

Revenio Group Corporation Stock Exchange Release February 10, 2022 at 10:15 a.m. (EET)

Revenio Group Corporation to transfer shares related to the share-based incentive scheme for 2019-2021

The Board of Directors of Revenio Group Corporation decided, on 10 February 2022, on the basis of the share issue authorisation granted to the Board of Directors by the company's Annual General Meeting held on 17 March 2021, to issue shares in a directed share issue without payment to pay the shares earned by the company's key persons during the performance period 2019-2021 LTI of the share-based incentive scheme.

The shares to be issued in the directed share issue without payment are issued in accordance with the terms and conditions of the company's current share-based incentive scheme to enhance the stability and work motivation of personnel, and thus there is an especially weighty financial reason for the share issue and for the derogation of the pre-emptive right of shareholders as provided in Chapter 9, Section 4(1) of the Finnish Limited Liability Companies Act. The key terms of the share-based incentive plan are described in the company's 2020 Remuneration Report.

A total of 10,802 of the company's treasury shares will be transferred in a directed issue free of charge to persons included in the share-based incentive scheme. After the transfers, the company holds 106,957 treasury shares.

Revenio Group Corporation
Board of Directors

For further information, please contact:
President and CEO Jouni Toijala, tel. +358 50 484 0085
jouni.toijala@revenio.fi

CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

DISTRIBUTION:
Nasdaq Helsinki Ltd
Financial Supervisory Authority
Main media
www.revenio.fi

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), perimeter and fundus imaging devices under the iCare brand. In addition, the Group's eye care software platform Oculo offers clinical communication, telehealth, remote patient monitoring and data analytics capabilities.

In 2021, the Group's net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

Revenio Group Corporation to transfer shares related to the share-based incentive scheme for 2019-2021